Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- heart failure (6)
- echocardiography (3)
- ischemic stroke (3)
- acute heart failure (2)
- amyloidosis (2)
- ejection fraction (2)
- guideline adherence (2)
- left ventricular ejection fraction (2)
- myocardial work (2)
- Alzheimer’s dementia (1)
- Brain atrophy (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Cardiovascular risk factors (1)
- Cardiovascular risk prediction (1)
- Carotid intima-media thickness (CIMT) (1)
- Carotid segment (1)
- Carotid ultrasound (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- GFAP (1)
- Glial fibrillary acidic protein (1)
- Heart failure (1)
- LV dilatation (1)
- Memory dysfunction (1)
- SGLT2 inhibitors (1)
- Stroke (1)
- Troponin (1)
- accuracy (1)
- adaptive immune response (1)
- age (1)
- anti-myocardial (1)
- arterial stiffening (1)
- atherosclerosis (1)
- autoantibody (1)
- awareness (1)
- biomarkers (1)
- calcification (1)
- cardiac imaging (1)
- cardiac training group (1)
- cardiac transplantation (1)
- cardiovascular risk factors (1)
- carotid artery disease (1)
- chronic kidney disease (1)
- coaptation line (1)
- cognitive impairment (1)
- comparability (1)
- computed tomography (1)
- coronary artery disease (1)
- coronary heart disease (1)
- deformation (1)
- disease score (1)
- disease severity (1)
- dynamic (1)
- euroaspire (1)
- expert opinion (1)
- feasibility (1)
- functional regurgitation (1)
- guideline implementation (1)
- heart failure training group (1)
- hypertension (1)
- inflammation (1)
- ischemic (1)
- leaflet (1)
- left ventricular geometric abnormality (1)
- left ventricular geometry (1)
- left ventricular mass (1)
- left ventricular performance (1)
- left ventricular remodeling (1)
- m exercise training (1)
- magnetic resonance imaging (1)
- mineralocorticoid antagonist (1)
- mitral valve (1)
- morbidity (1)
- mortality (1)
- myocardial work efficiency (1)
- natriuretic peptide (1)
- neurofilament light chain (1)
- normal values (1)
- pharmacotherapy (1)
- phosphorylated tau protein (1)
- point-of-care echocardiography (1)
- population-based study (1)
- preserved ejection fraction (1)
- prevalence (1)
- primary prevention (1)
- prognosis (1)
- recovery (1)
- reference data (1)
- regression analysis (1)
- renal function (1)
- risk factor control (1)
- sex differences (1)
- stem cell transplantation (1)
- stroke unit (1)
- systolic dysfunction (1)
- tenting (1)
- therapeutic approach (1)
- three-dimensional echocardiography (1)
- transient ischemic attack (1)
- troponin (1)
Institute
- Medizinische Klinik und Poliklinik I (18)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (13)
- Institut für Klinische Epidemiologie und Biometrie (10)
- Neurologische Klinik und Poliklinik (6)
- Medizinische Klinik und Poliklinik II (3)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Informatik (1)
- Institut für Sportwissenschaft (1)
- Institut für Virologie und Immunbiologie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Pathologisches Institut (1)
Sonstige beteiligte Institutionen
Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study
(2024)
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.